{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:40:02Z","timestamp":1748295602410,"version":"3.41.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review summarizes latest developments in treatment of juvenile spondyloarthritis (JSpA), specifically enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>There has been addition of biologic disease modifying antirheumatic drugs (bDMARDs) beyond tumor necrosis factor inhibitors (TNFi) for JSpA such as IL-17 blockers, IL-23 blockers, and janus activating kinase inhibitors with favorable safety profile. Conducting robust clinical trials for this subpopulation of JIA remains a challenge; extrapolation studies are being used to obtain approval from regulatory agencies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Newer drug therapies have expanded the scope of treatment for patients with JSpA. bDMARDs such as adalimumab, etanercept, infliximab, and secukinumab have demonstrated clinically significant treatment efficacy in ERA and JPsA. Based on extrapolation studies, intravenous golimumab, etanercept, abatacept, and ustekinumab have gained Food and Drug Administration (FDA) approval for JPsA. Long-term follow-up studies continue to demonstrate acceptable safety profiles. There is need for more real-world data on drug efficacy from Registry studies and research on effective de-escalation strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001016","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T15:00:58Z","timestamp":1713538858000},"page":"295-301","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Drug therapy in juvenile spondyloarthritis"],"prefix":"10.1097","volume":"36","author":[{"given":"Hemalatha","family":"Srinivasalu","sequence":"first","affiliation":[{"name":"GW University School of Medicine"},{"name":"Division of Rheumatology, Children's National Hospital, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Simpson","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Children's National Hospital, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew L.","family":"Stoll","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"R1-20250526","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/art.1780250902","article-title":"A syndrome of seronegative enthesopathy and arthropathy in children","volume":"25","author":"Rosenberg","year":"1982","journal-title":"Arthritis Rheum"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11926-020-0880-3","article-title":"The challenges and opportunities of classifying childhood arthritis","volume":"22","author":"Rumsey","year":"2020","journal-title":"Curr Rheum Rep"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/acr.24529","article-title":"Children with enthesitis-related arthritis and possible benefits from treatments for adults with spondyloarthritis","volume":"74","author":"Weiss","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41584-021-00590-6","article-title":"Biological classification of childhood arthritis: roadmap to a molecular nomenclature","volume":"17","author":"Nigrovic","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/ard.61.10.941","article-title":"A 26\u200aweek randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies","volume":"61","author":"Burgos-Vargas","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/acr.22657","article-title":"A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis","volume":"67","author":"Burgos-Vargas","year":"2015","journal-title":"Arthritis Care Res(Hoboken)"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","article-title":"Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study","volume":"73","author":"Horneff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.39145","article-title":"Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study","volume":"67","author":"Horneff","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13075-022-02877-9","article-title":"A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis","volume":"24","author":"Burgos-Vargas","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.40884","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken)"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.42037","article-title":"2021 American College of Rheumatology Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol (Hoboken)"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/ard-2022-222849","article-title":"Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial","volume":"82","author":"Brunner","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1093\/rheumatology\/keab021","article-title":"Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis","volume":"60","author":"Ruperto","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT Study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken)"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40272-022-00533-y","article-title":"Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations","volume":"24","author":"Leu","year":"2022","journal-title":"Paediatr Drugs"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17\u200ayears with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/bjd.19018","article-title":"Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (\u2265 6 to < 12\u200ayears of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study","volume":"183","author":"Philipp","year":"2020","journal-title":"Br J Dermatol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1\u200ayear results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/bjd.15722","article-title":"Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)","volume":"177","author":"Blauvelt","year":"2017","journal-title":"Br J Dermatol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40466","article-title":"Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study","volume":"70","author":"Brunner","year":"2018","journal-title":"Arthritis Rheumatol (Hoboken)"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","article-title":"Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/art.39234","article-title":"Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years","volume":"67","author":"Lovell","year":"2015","journal-title":"Arthritis Rheumatol (Hoboken)"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"New Engl J Med"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"e002943","DOI":"10.1136\/rmdopen-2022-002943","article-title":"Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry","volume":"9","author":"Correll","year":"2023","journal-title":"RMD open"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12969-016-0085-5","article-title":"Clinical outcome measures in juvenile idiopathic arthritis","volume":"14","author":"Consolaro","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","article-title":"Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial","volume":"402","author":"Ramanan","year":"2023","journal-title":"Lancet"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/rheumatology\/kead183","article-title":"Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis","volume":"63","author":"Vojinovi\u0107","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13075-020-02326-5","article-title":"Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry","volume":"22","author":"Armaroli","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/acr.24044","article-title":"Safety and effectiveness of adalimumab in patients with polyarticular course of juvenile idiopathic arthritis: STRIVE Registry Seven-Year Interim Results","volume":"72","author":"Brunner","year":"2020","journal-title":"Arthritis Care Res"},{"key":"R37-20250526","first-page":"keae025","article-title":"Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO\/PRCSG registry","author":"Lovell","year":"2024","journal-title":"Rheumatology (Oxford, England)"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/BOR.0b013e328348b278","article-title":"Psoriatic juvenile idiopathic arthritis: a tale of two subgroups","volume":"23","author":"Stoll","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/acr.22411","article-title":"Development and retrospective validation of the juvenile spondyloarthritis disease activity index","volume":"66","author":"Weiss","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3899\/jrheum.220509","article-title":"Modified Juvenile Spondyloarthritis Disease Activity Index in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry","volume":"50","author":"Srinivasalu","year":"2023","journal-title":"J Rheumatol"},{"issue":"(Suppl 9)","key":"R41-20250526","article-title":"Validation of the Juvenile Spondyloarthritis Disease Activity Index in a prospective clinical trial setting [abstract]","volume":"75","author":"Weiss","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1546-0096-12-35","article-title":"Predictors of response to methotrexate in juvenile idiopathic arthritis","volume":"12","author":"Albarouni","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/jcm10040568","article-title":"Enthesitis related arthritis in a longitudinal Southeast Asian Registry: high prevalence of HLA-B27, different sacroiliitis risk factors and less common drug-free remission","volume":"10","author":"Arkachaisri","year":"2021","journal-title":"J Clin Med"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12969-017-0178-9","article-title":"Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12\u200amonths: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia","volume":"15","author":"Alexeeva","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"issue":"(Suppl 9)","key":"R45-20250526","article-title":"Clinical disease manifestations associated with tnf inhibitor non-response in juvenile spondyloarthritis [abstract]","volume":"75","author":"Oliver","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3899\/jrheum.161078","article-title":"Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: a survey of the childhood arthritis and rheumatology research alliance","volume":"44","author":"Horton","year":"2017","journal-title":"J Rheumatol"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/annrheumdis-2014-207164","article-title":"The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort","volume":"75","author":"Guzman","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13063-022-07038-6","article-title":"Biologic Abatement and Capturing Kids\u2019 Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA): study protocol for a randomized pragmatic trial","volume":"24","author":"Weiss","year":"2023","journal-title":"Trials"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3899\/jrheum.210709","article-title":"Consensus approach to a treat-to-target strategy in juvenile idiopathic arthritis care: report from the 2020 PR-COIN Consensus Conference","volume":"49","author":"El Tal","year":"2022","journal-title":"J Rheumatol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:16:09Z","timestamp":1748294169000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001016","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"type":"print","value":"1040-8711"},{"type":"electronic","value":"1531-6963"}],"subject":[],"published":{"date-parts":[[2024,4,19]]}}}